1. Vogel A, Saborowski A: Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. Cancer treatment reviews 2020, 82:101946.
2. Tien A, Chien C, Chen Y, Lin L, Chien C: Fruiting Bodies of Antrodia cinnamomea and Its Active Triterpenoid, Antcin K, Ameliorates N-Nitrosodiethylamine-Induced Hepatic Inflammation, Fibrosis and Carcinogenesis in Rats. The American journal of Chinese medicine 2017, 45:173-198.
3. Chen X, Kang R, Kroemer G, Tang D: Broadening horizons: the role of ferroptosis in cancer. Nature reviews Clinical oncology 2021, 18:280-296.
4. Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, Koppula P, Wu S, Zhuang L, Fang B, et al: DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 2021, 593:586-590.
5. Tang Y, Li C, Zhang YJ, Wu ZH: Ferroptosis-Related Long Non-Coding RNA signature predicts the prognosis of Head and neck squamous cell carcinoma. Int J Biol Sci 2021, 17:702-711.
6. Li X, Pongor L, Tang W, Das S, Muys B, Jones M, Lazar S, Dangelmaier E, Hartford C, Grammatikakis I, et al: A small protein encoded by a putative lncRNA regulates apoptosis and tumorigenicity in human colorectal cancer cells. eLife 2020, 9.
7. Wang Z, Pan J, Hu J, Zhang J, Huang L, Huang Y, Liao C, Yang C, Chen Z, Wang Y, et al: SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine. Cell reports 2022, 39:110813.
8. Li B, Kang H, Xiao Y, Du Y, Xiao Y, Song G, Zhang Y, Guo Y, Yang F, He F, Yang S: LncRNA GAL promotes colorectal cancer liver metastasis through stabilizing GLUT1. Oncogene 2022, 41:1882-1894.
9. Zhou N, Bao J: FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford) 2020, 2020.
10. Wolstenholme JT, Rissman EF, Bekiranov S: Sexual differentiation in the developing mouse brain: contributions of sex chromosome genes. Genes Brain Behav 2013, 12:166-180.
11. Chen J, Bardes EE, Aronow BJ, Jegga AG: ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 2009, 37:W305-311.
12. Costin BN, Wolen AR, Fitting S, Shelton KL, Miles MF: Role of adrenal glucocorticoid signaling in prefrontal cortex gene expression and acute behavioral responses to ethanol. Alcohol Clin Exp Res 2013, 37:57-66.
13. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
14. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP: GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 2007, 23:3251-3253.
15. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z: Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep 2017, 18:248-262.
16. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA: Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015, 12:453-457.
17. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013, 4:2612.
18. Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D, et al: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med 2019, 11:34.
19. Aran D, Hu Z, Butte AJ: xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 2017, 18:220.
20. Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 2016, 17:218.
21. Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D: Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife 2017, 6.
22. Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al: Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol 2016, 17:174.
23. Yi M, Nissley DV, McCormick F, Stephens RM: ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications. Sci Rep 2020, 10:10258.
24. Bridges M, Daulagala A, Kourtidis A: LNCcation: lncRNA localization and function. The Journal of cell biology 2021, 220.
25. Chen X, Kang R, Kroemer G, Tang D: Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol 2021, 18:280-296.
26. Bu X, Ma L, Liu S, Wen D, Kan A, Xu Y, Lin X, Shi M: A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. Cancer Cell Int 2022, 22:95.
27. Zhong F, Liu S, Hu D, Chen L: LncRNA AC099850.3 promotes hepatocellular carcinoma proliferation and invasion through PRR11/PI3K/AKT axis and is associated with patients prognosis. J Cancer 2022, 13:1048-1060.
28. Li X, Zhang S, Zhang S, Kuang W, Tang C: Inflammatory Response-Related Long Non-Coding RNA Signature Predicts the Prognosis of Hepatocellular Carcinoma. J Oncol 2022, 2022:9917244.
29. Wang Q, Tang Y, Ge Y, Zhang S, Zheng M: Long non-coding RNA NRAV enhances proliferation and invasion of hepatocellular carcinoma cells by modulating the Wnt/β-catenin signaling pathway. Bioengineered 2022, 13:10026-10037.
30. Nie Y, Li Y, Xu Y, Jiao Y, Li W: Long non-coding RNA BACE1-AS is an independent unfavorable prognostic factor in liver cancer. Oncol Lett 2020, 20:202.
31. Xia X, Zhang H, Xia P, Zhu Y, Liu J, Xu K, Yuan Y: Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma. Front Oncol 2021, 11:733595.
32. He H, Wang Y, Ye P, Yi D, Cheng Y, Tang H, Zhu Z, Wang X, Jin S: Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma. J Exp Clin Cancer Res 2020, 39:159.
33. Jiao Y, Li Y, Jia B, Chen Q, Pan G, Hua F, Liu Y: The prognostic value of lncRNA SNHG4 and its potential mechanism in liver cancer. Biosci Rep 2020, 40.
34. Fang C, Liu S, Feng K, Huang C, Zhang Y, Wang J, Lin H, Wang J, Zhong C: Ferroptosis-related lncRNA signature predicts the prognosis and immune microenvironment of hepatocellular carcinoma. Sci Rep 2022, 12:6642.
35. Wu ZH, Li ZW, Yang DL, Liu J: Development and Validation of a Pyroptosis-Related Long Non-coding RNA Signature for Hepatocellular Carcinoma. Front Cell Dev Biol 2021, 9:713925.
36. Gong A, Luo X, Tan Y, Chen H, Luo G: High expression of C10orf91 and LINC01224 in hepatocellular carcinoma and poor prognosis. Am J Transl Res 2022, 14:2567-2579.
37. Chen T, Liu R, Niu Y, Mo H, Wang H, Lu Y, Wang L, Sun L, Wang Y, Tu K, Liu Q: HIF-1α-activated long non-coding RNA KDM4A-AS1 promotes hepatocellular carcinoma progression via the miR-411-5p/KPNA2/AKT pathway. Cell Death Dis 2021, 12:1152.
38. Zhao QJ, Zhang J, Xu L, Liu FF: Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. World J Gastroenterol 2018, 24:3426-3439.
39. Chen ZA, Tian H, Yao DM, Zhang Y, Feng ZJ, Yang CJ: Identification of a Ferroptosis-Related Signature Model Including mRNAs and lncRNAs for Predicting Prognosis and Immune Activity in Hepatocellular Carcinoma. Front Oncol 2021, 11:738477.
40. Guo C, Zhou S, Yi W, Yang P, Li O, Liu J, Peng C: Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma. Exp Mol Pathol 2021, 120:104638.
41. Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C, Dai X, Li Z, Wu G: Ferroptosis: A Novel Anti-tumor Action for Cisplatin. Cancer Res Treat 2018, 50:445-460.
42. Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al: CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 2019, 569:270-274.
43. Xu Q, Wang Y, Huang W: Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma. Int Immunopharmacol 2021, 92:107333.
44. Feng Y, Hu X, Ma K, Zhang B, Sun C: Genome-Wide Screening Identifies Prognostic Long Noncoding RNAs in Hepatocellular Carcinoma. Biomed Res Int 2021, 2021:6640652.
45. Liu Y, Zhang X, Zhang J, Tan J, Li J, Song Z: Development and Validation of a Combined Ferroptosis and Immune Prognostic Classifier for Hepatocellular Carcinoma. Front Cell Dev Biol 2020, 8:596679.
46. Liang JY, Wang DS, Lin HC, Chen XX, Yang H, Zheng Y, Li YH: A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma. Int J Biol Sci 2020, 16:2430-2441.
47. Liu DL, Wu MY, Zhang TN, Wang CG: Ferroptosis Regulator Modification Patterns and Tumor Microenvironment Immune Infiltration Characterization in Hepatocellular Carcinoma. Front Mol Biosci 2022, 9:807502.